Los Angeles Mesothelioma Lawyer Directory
Thursday, January 21, 2016
Helix BioPharma Corp. Initiates Enrollment in the Second Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
… certain patients with non-small cell
lung
cancer
("NSCLC"). LDOS001 is …
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment